BR112013026698A2 - topical type formulations comprising cyclic depsipeptide - Google Patents

topical type formulations comprising cyclic depsipeptide

Info

Publication number
BR112013026698A2
BR112013026698A2 BR112013026698A BR112013026698A BR112013026698A2 BR 112013026698 A2 BR112013026698 A2 BR 112013026698A2 BR 112013026698 A BR112013026698 A BR 112013026698A BR 112013026698 A BR112013026698 A BR 112013026698A BR 112013026698 A2 BR112013026698 A2 BR 112013026698A2
Authority
BR
Brazil
Prior art keywords
cyclic depsipeptide
type formulations
topical type
topical
compositions
Prior art date
Application number
BR112013026698A
Other languages
Portuguese (pt)
Inventor
Claire Haug
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013026698(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013026698A2 publication Critical patent/BR112013026698A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "formulações do tipo tópica compreendendo depsipeptídeo cíclico". a presente invenção refere-se às novas composições farmacêuticas tópicas nas quais o agente ativo é um depsipeptídeo cíclico de fórmula (ii) (ii) e a métodos para a fabricação de tais composições. o pedido descreve, em particular, unguentos hidrofóbicos que compreendem uma base hidrofóbica e um agente de consistência, preferivelmente o miristato de isopropila.patent summary: "topical type formulations comprising cyclic depsipeptide". The present invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (ii) (ii) and to methods for the manufacture of such compositions. In particular, the application describes hydrophobic ointments comprising a hydrophobic base and a consistency agent, preferably isopropyl myristate.

BR112013026698A 2011-04-20 2012-04-18 topical type formulations comprising cyclic depsipeptide BR112013026698A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477297P 2011-04-20 2011-04-20
PCT/IB2012/051946 WO2012143868A1 (en) 2011-04-20 2012-04-18 Suspension type topical formulations comprising cyclic depsipeptide

Publications (1)

Publication Number Publication Date
BR112013026698A2 true BR112013026698A2 (en) 2016-12-27

Family

ID=46148908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026698A BR112013026698A2 (en) 2011-04-20 2012-04-18 topical type formulations comprising cyclic depsipeptide

Country Status (21)

Country Link
US (2) US8680054B2 (en)
EP (1) EP2699231B1 (en)
JP (1) JP5906304B2 (en)
KR (1) KR101612170B1 (en)
CN (1) CN103476396B (en)
AR (1) AR086109A1 (en)
AU (1) AU2012245960B2 (en)
BR (1) BR112013026698A2 (en)
CA (1) CA2833326A1 (en)
CL (1) CL2013003036A1 (en)
EA (1) EA201391555A1 (en)
ES (1) ES2651639T3 (en)
GT (1) GT201300257A (en)
IL (1) IL228863A0 (en)
MA (1) MA35158B1 (en)
MX (1) MX338156B (en)
PE (1) PE20141068A1 (en)
SG (1) SG11201402441WA (en)
TN (1) TN2013000386A1 (en)
TW (1) TW201247218A (en)
WO (1) WO2012143868A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001849A (en) 2007-08-17 2010-03-10 Novartis Ag Cyclic depsipeptides.
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
CN108888590A (en) * 2018-08-06 2018-11-27 江苏知原药业有限公司 The topical formulations of suspension type comprising tacrolimus
EP4114358A4 (en) * 2020-03-06 2024-03-27 Lifemax Laboratories Inc Topical pharmaceutical formulations of a cyclic depsipeptide

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (en) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclic acetals of N-acylglutamic acid - γ - semialdehydes, processes for their preparation and their use
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (en) 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, extraction process, means with chondrams and mixed culture for chondramide production
DE19828043A1 (en) * 1998-06-24 1999-12-30 Bayer Ag Use of cyclooctadepsipeptide derivatives
JP2000154198A (en) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd Solid phase synthesis of cyclic depsipeptide and its intermediate
JP2001131085A (en) * 1999-08-25 2001-05-15 Saitama Daiichi Seiyaku Kk Medicinal composition for transdermal and transmucosal absorption
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
CN101152185B (en) 2003-06-06 2010-12-08 阿里克斯股份公司 Use of heterocyclic compounds as SCCE inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
DE10358525A1 (en) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasiticides Means for topical application
WO2005075667A1 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
JP2009532664A (en) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ Identification and use of novopeptides for the treatment of cancer
MX2010001849A (en) * 2007-08-17 2010-03-10 Novartis Ag Cyclic depsipeptides.
ES2527298T3 (en) 2007-08-17 2015-01-22 Novartis Ag Use of cyclic depsypeptides to inhibit calicrein 7
DE102007052391A1 (en) * 2007-10-31 2009-05-07 Henkel Ag & Co. Kgaa Matt wax
JP2010241784A (en) * 2008-06-19 2010-10-28 Mitsubishi Tanabe Pharma Corp Transdermally dosing preparation
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
KR101004362B1 (en) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 TNF-α AND TWEAK COUPLED ANTAGONIST FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
WO2012035468A2 (en) 2010-09-14 2012-03-22 Trima - Israel Pharmaceutical Products Maabarot Ltd. Foamable topical composition
CN106924216A (en) 2011-01-24 2017-07-07 安特里奥公司 Nanoparticulate compositions, its preparation and their purposes
EP2667854B1 (en) 2011-01-24 2019-01-16 Anterios, Inc. Nanoparticle compositions
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates

Also Published As

Publication number Publication date
EA201391555A1 (en) 2014-11-28
EP2699231B1 (en) 2017-09-13
US8680054B2 (en) 2014-03-25
KR20130133295A (en) 2013-12-06
US20120270796A1 (en) 2012-10-25
MX338156B (en) 2016-04-05
AR086109A1 (en) 2013-11-20
US20140162959A1 (en) 2014-06-12
TW201247218A (en) 2012-12-01
AU2012245960B2 (en) 2014-09-25
TN2013000386A1 (en) 2015-01-20
JP5906304B2 (en) 2016-04-20
KR101612170B1 (en) 2016-04-12
MX2013012187A (en) 2013-11-04
MA35158B1 (en) 2014-06-02
WO2012143868A1 (en) 2012-10-26
IL228863A0 (en) 2013-12-31
NZ615551A (en) 2015-08-28
JP2014512377A (en) 2014-05-22
GT201300257A (en) 2015-02-19
US9114110B2 (en) 2015-08-25
CL2013003036A1 (en) 2014-04-04
AU2012245960A1 (en) 2013-10-17
EP2699231A1 (en) 2014-02-26
ES2651639T3 (en) 2018-01-29
CN103476396A (en) 2013-12-25
CA2833326A1 (en) 2012-10-26
SG11201402441WA (en) 2014-09-26
CN103476396B (en) 2015-08-05
PE20141068A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
BR112013026698A2 (en) topical type formulations comprising cyclic depsipeptide
CY1118813T1 (en) PHARMACEUTICAL COMPOSITIONS OF TRAMADOL AND COXYL-CYLINDERS
BR112013022495A2 (en) tapentadol aqueous pharmaceutical formulation for oral administration
BR112015011244A8 (en) long-acting or directed cell reaction compstatin analogs and related compositions and methods
BR112013031268A2 (en) "pramlintide analog polypeptides, use thereof, pharmaceutical composition comprising said polypeptides and method of preparing said composition".
BR112013005125A2 (en) pridopidine analogues useful as dopaminergic stabilizers
BR112016013299A2 (en) COMPOUND
BR112015005972A2 (en) benzoimidazole carboxylic acid amide type derivatives as apj receptor modulators
RS53559B1 (en) Long-acting formulations of insulins
BR112014005358A2 (en) pain relief composition comprising a selective trpv1 agonist, and its manufacture and use
BRPI0915119B8 (en) use of carrageenan iota
BR112016001446A8 (en) therapeutic compositions, combination product, in vitro use of flecainide and flecainide
BR112013028816A2 (en) "compstatin analogs, composition comprising them and use thereof".
BR112013004766A2 (en) Substituted 2-amino-quinoline-3-carboxamides as kcnq2 / 3 modulators
UY30762A1 (en) SMOKE SALT OF (ALFA S, BETA R) -6-BROMO-ALFA- [2 (DIMETILAMINO) ETIL] -2-METOXI-ALFA-1-NAFTALENIL-BETA-PHENYL-3-QUINOLINAETHANOL
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
BR112015011430A2 (en) composition for immediate and prolonged release
BR112014002025A2 (en) particles comprising polyacrylate-based active compounds
BR112015031878A2 (en) pharmaceutical composition
BR112013024824A2 (en) Isopentyl esters for use in cosmetic, dermatological or pharmaceutical compositions
BR112015027017A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
BR112013004562A2 (en) Substituted 2-oxyquinoline-3-carboxamides as modulators kcnq2 / 3
BR112014002674A2 (en) Substituted 3- (biphenyl-3-yl) -4-hydroxy-8-methoxy-1-azaspiro [4.5] dec-3-en-2-ones
TR201004464A2 (en) Formulation for bone resorption.
AR084197A1 (en) COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF SKIN DISORDERS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]